Core Insights - Smith+Nephew will support select players at The Championships, Wimbledon in 2025, continuing its commitment to showcase its Sports Medicine product portfolio and the purpose of 'Life Unlimited' [1][6] - The company had a successful inaugural sponsorship during Wimbledon 2024, highlighting its brand and technology aimed at aiding athletes in recovery and performance [3] Product Portfolio - The REGENETEN Bioinductive Implant has been used in over 150,000 procedures globally since 2014, showing lower re-tear rates for rotator cuff surgeries compared to conventional methods [4] - The CARTIHEAL AGILI-C Cartilage Repair Implant is the only device approved for treating knee cartilage and osteochondral defects in patients with mild to moderate osteoarthritis, demonstrating significant post-operative improvements [4] - The Q-FIX KNOTLESS All-Suture Anchor offers enhanced fixation strength and aims to set a new benchmark for soft tissue security in joint repair [4] Company Overview - Smith+Nephew, founded in 1856 in Hull, UK, operates in around 100 countries and generated annual sales of $5.8 billion in 2024 [7] - The company focuses on the repair, regeneration, and replacement of soft and hard tissue, with a mission to restore patients' bodies and self-belief through innovative technologies [6]